We investigated whether enhanced APN expression provides therapeutic benefit against AngII-induced AAA by injecting AdGFP or AdAPN into AngII-infused hyperlipidemic LDLR−/− 11, 18. This evidence concerns the gene LDLR and triple-A syndrome.